This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning ...

If you have been watching CRISPR Therapeutics (CRSP) lately, you have probably noticed the sharp rebound in its stock price. The rally was set off by compelling developments, specifically Casgevy’s ...

Cathie Wood’s ARK ETFs have disclosed their daily trades for Wednesday, August 27th, 2025, with significant activity in the tech and biotech sectors. Leading the charge was a substantial investment in ...